Molecular profiling: From TCGA to routine practicePerhaps the most significant shift in endometrial cancer management has been the move from histological-based classification alone to molecular stratification. Immunotherapy: A new standard in advanced diseaseHistorically there were significant challenges in the treatment of advanced or recurrent endometrial cancer. For clinicians, the take-home points are: molecular testing at diagnosis is no longer optional in endometrial cancer. These findings remain observational or early-phase, and GLP-1RAs are not yet incorporated into any endometrial cancer treatment guideline. Endometrial cancer care in 2026 in Ireland looks markedly different from a decade ago.